Roche lupus drug Gazyva gets FDA filing acceptance
Roche (OTCQX: RHHBY) said the FDA accepted its supplemental BLA for Gazyva/Gazyvaro (obinutuzumab)…
Roche lupus drug cuts disease activity in phase III
Roche (OTCQX: RHHBY) announced NEJM publication of phase III ALLEGORY data showing Gazyva/Gazyvaro (obinutuzumab) plus standard therapy significantly…
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4,…